Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Morphic Therapeutic completes $51.5mm Series A round

Executive Summary

Morphic Therapeutic Inc. (targeting integrin receptors) completed a $51.5mm Series A financing. SR One and Pfizer Venture Investments co-led and were joined by new investors Omega Funds and AbbVie Ventures, and returning shareholders Polaris Partners, founder and board member Tim Springer, PhD (TA Springer), molecular modeling software company Schrodinger, and ShangPharma Investment Group.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies